Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q38440279)
Watch
English
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
scientific article published on 23 April 2015
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
review article
1 reference
stated in
Europe PubMed Central
title
Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
author
Atsushi Yonezawa
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
Suparna Dutt
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
Sylvia Jeewon Kim
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
author name string
Cariad Chester
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
Holbrook E Kohrt
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
language of work or name
English
0 references
publication date
23 April 2015
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
published in
Clinical Cancer Research
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
volume
21
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
issue
14
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
page(s)
3113-3120
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
cites work
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Acquired resistance to EGFR-targeted therapies in colorectal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Targeting CD137 enhances the efficacy of cetuximab.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Signatures of human NK cell development and terminal differentiation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Antibody therapeutics in cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Molecular mechanisms of T cell co-stimulation and co-inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Advances in targeting cell surface signalling molecules for immune modulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combination strategies to enhance antitumor ADCC.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Immunotherapy of cancer with 4-1BB.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
CD1d-based combination therapy eradicates established tumors in mice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
The role of TNF superfamily members in T-cell function and diseases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Human natural killer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
cDNA sequences of two inducible T-cell genes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
6 September 2017
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
14 September 2017
Eradication of established tumors in mice by a combination antibody-based therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
14 September 2017
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
14 September 2017
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
14 September 2017
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
14 September 2017
Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
23 June 2018
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
23 June 2018
Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
4-1BB-mediated immunotherapy of rheumatoid arthritis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
31 August 2018
Cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
1 October 2018
Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
1 October 2018
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5422104
retrieved
1 October 2018
Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25908780
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25908780
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25908780
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25908780
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25908780
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/1078-0432.CCR-15-0263
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
PMC publication ID
5422104
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
PubMed publication ID
25908780
1 reference
stated in
Europe PubMed Central
PMC publication ID
5422104
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25908780%20AND%20SRC:MED&resulttype=core&format=json
retrieved
6 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
